Aardvark Therapeutics Investors Have Until October 13 to Seek Lead Plaintiff Role

Faruqi & Faruqi, LLP, a leading national securities law firm, has reminded investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) of an upcoming deadline to seek the role of lead plaintiff in a federal securities class action lawsuit. The deadline is October 13, 2026.

The lawsuit, filed against Aardvark, alleges that the company and its executives violated federal securities laws by making false and misleading statements and failing to disclose that the Offering Documents, issued in connection with the company's initial public offering (IPO) on February 13, 2025, were negligently prepared. According to the complaint, the Offering Documents contained untrue statements of material fact or omitted necessary information to make the statements not misleading.

The class period for the lawsuit spans from February 13, 2025, to May 14, 2026. Investors who purchased or acquired Aardvark securities during this period and suffered losses are eligible to participate in the lawsuit. The complaint specifically alleges that the Offering Documents and public statements made by the company's executives were misleading regarding the safety and clinical, regulatory, and commercial prospects of ARD-101, the company's lead drug candidate.

On May 14, 2026, the U.S. Food and Drug Administration (FDA) placed a full clinical hold on Aardvark's investigational new drug application (IND) for ARD-101, related to the company's previously announced voluntary pause. This news further impacted Aardvark's stock price, causing it to drop by 32.1% to close at $4.57 per share on May 15, 2026.

Faruqi & Faruqi, LLP, is encouraging investors who believe they may have suffered losses due to these alleged misrepresentations to contact partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). The firm has recovered hundreds of millions of dollars for investors since its founding in 1995 and is now representing those who have been affected by Aardvark's alleged securities violations.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members and directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.